Submitted: 15 Sep 2023
Accepted: 16 Feb 2024
ePublished: 09 Mar 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Ren Endocrinol. 2024;10: e25134.
doi: 10.34172/jre.2024.25134
  Abstract View: 266
  PDF Download: 155

Original Article

Factors affecting the survival of patients with refractory and relapsed acute myeloid leukemia

Maryam Ghazizadeh 1 ORCID logo, Matin Ghazizadeh 2* ORCID logo

1 Department of Hematology-Oncology, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2 Department of Otolaryngology, Head and Neck Surgery, Taleghani, Tehran, Iran.
*Corresponding Author: Matin Ghazizadeh, Email: matinghazizadeh@sbmu.ac.ir, Email: matinghazizadeh@hotmail.com


Introduction: Acute myeloid leukemia (AML) is one of the poor prognostic diseases. It relapses in more than half of young and 85% of old patients. AML patients with good prognosis are candidates for transplantation in the second remission and patients with poor or intermediate prognosis are candidates in the first remission.

Objectives: In this study, the survival of patients with AML, and the effect of bone marrow transplantation (BMT) were evaluated.

Patients and Methods: This retrospective study was carried out on 30 patients with relapsed and refractory AML who were admitted to Taleghani Hospital. The overall survival (OS) rate and effective factors (WBC count, platelet count, cytogenesis) were determined. Collected data were analyzed by using version 24 of SPSS and via appropriate statistical tests. P<0.05 was considered statistically significant.

Results: Thirty patients—56% with refractory AML and 43% with relapsed AML—were enrolled in the study. Complete remission was achieved in 23% of patients, the others did not achieve remission despite salvage chemotherapy. Relapse-free survival (RFS) in these patients was 12±1weeks. Only 3% of patients received BMT. There was a statistically significant association between WBC count, platelet count, cytogenesis study, and OS.

Conclusion: Relapsed or refractory AML is a disease with a very poor prognosis, despite salvage therapy. So, we recommend that all patients with AML should receive BMT in their first remission.

Citation: Ghazizadeh M, Ghazizadeh M. Factors affecting the survival of patients with refractory and relapsed acute myeloid leukemia. J Ren Endocrinol. 2024;10:e25134. doi: 10.34172/jre.2024.25134.
First Name
Last Name
Email Address
Security code

Abstract View: 267

Your browser does not support the canvas element.

PDF Download: 155

Your browser does not support the canvas element.